vs
Side-by-side financial comparison of SITIME Corp (SITM) and Vericel Corp (VCEL). Click either name above to swap in a different company.
SITIME Corp is the larger business by last-quarter revenue ($113.3M vs $92.9M, roughly 1.2× Vericel Corp). Vericel Corp runs the higher net margin — 25.0% vs 8.1%, a 16.9% gap on every dollar of revenue. On growth, SITIME Corp posted the faster year-over-year revenue change (66.3% vs 23.3%). SITIME Corp produced more free cash flow last quarter ($13.0M vs $12.8M). Over the past eight quarters, SITIME Corp's revenue compounded faster (85.2% CAGR vs 34.6%).
SiTime Corporation is a publicly traded fabless chipmaker based in Santa Clara, California that develops micro-electromechanical systems (MEMS), used for timing devices in electronics.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
SITM vs VCEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $113.3M | $92.9M |
| Net Profit | $9.2M | $23.2M |
| Gross Margin | 56.4% | 78.7% |
| Operating Margin | 1.6% | 24.1% |
| Net Margin | 8.1% | 25.0% |
| Revenue YoY | 66.3% | 23.3% |
| Net Profit YoY | 148.7% | 17.3% |
| EPS (diluted) | $0.44 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $113.3M | $92.9M | ||
| Q3 25 | $83.6M | $67.5M | ||
| Q2 25 | $69.5M | $63.2M | ||
| Q1 25 | $60.3M | $52.6M | ||
| Q4 24 | $68.1M | $75.4M | ||
| Q3 24 | $57.7M | $57.9M | ||
| Q2 24 | $43.9M | $52.7M | ||
| Q1 24 | $33.0M | $51.3M |
| Q4 25 | $9.2M | $23.2M | ||
| Q3 25 | $-8.0M | $5.1M | ||
| Q2 25 | $-20.2M | $-553.0K | ||
| Q1 25 | $-23.9M | $-11.2M | ||
| Q4 24 | $-18.8M | $19.8M | ||
| Q3 24 | $-19.3M | $-901.0K | ||
| Q2 24 | $-26.8M | $-4.7M | ||
| Q1 24 | $-28.7M | $-3.9M |
| Q4 25 | 56.4% | 78.7% | ||
| Q3 25 | 53.5% | 73.5% | ||
| Q2 25 | 51.9% | 73.7% | ||
| Q1 25 | 50.3% | 69.0% | ||
| Q4 24 | 52.6% | 77.6% | ||
| Q3 24 | 51.1% | 71.9% | ||
| Q2 24 | 49.1% | 69.5% | ||
| Q1 24 | 53.5% | 68.9% |
| Q4 25 | 1.6% | 24.1% | ||
| Q3 25 | -19.2% | 5.1% | ||
| Q2 25 | -35.4% | -3.2% | ||
| Q1 25 | -46.6% | -24.3% | ||
| Q4 24 | -33.8% | 24.5% | ||
| Q3 24 | -43.1% | -4.3% | ||
| Q2 24 | -73.7% | -11.5% | ||
| Q1 24 | -106.1% | -10.7% |
| Q4 25 | 8.1% | 25.0% | ||
| Q3 25 | -9.6% | 7.5% | ||
| Q2 25 | -29.0% | -0.9% | ||
| Q1 25 | -39.6% | -21.4% | ||
| Q4 24 | -27.6% | 26.3% | ||
| Q3 24 | -33.5% | -1.6% | ||
| Q2 24 | -61.0% | -8.9% | ||
| Q1 24 | -86.9% | -7.5% |
| Q4 25 | $0.44 | $0.46 | ||
| Q3 25 | $-0.31 | $0.10 | ||
| Q2 25 | $-0.84 | $-0.01 | ||
| Q1 25 | $-1.01 | $-0.23 | ||
| Q4 24 | $-0.80 | $0.40 | ||
| Q3 24 | $-0.83 | $-0.02 | ||
| Q2 24 | $-1.16 | $-0.10 | ||
| Q1 24 | $-1.26 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $354.6M |
| Total Assets | $1.3B | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $137.5M | ||
| Q3 25 | — | $135.4M | ||
| Q2 25 | — | $116.9M | ||
| Q1 25 | — | $112.9M | ||
| Q4 24 | — | $116.2M | ||
| Q3 24 | — | $101.7M | ||
| Q2 24 | — | $102.5M | ||
| Q1 24 | — | $110.6M |
| Q4 25 | $1.2B | $354.6M | ||
| Q3 25 | $1.1B | $321.9M | ||
| Q2 25 | $1.1B | $306.8M | ||
| Q1 25 | $692.5M | $295.5M | ||
| Q4 24 | $699.7M | $292.0M | ||
| Q3 24 | $696.2M | $257.5M | ||
| Q2 24 | $692.5M | $243.0M | ||
| Q1 24 | $696.2M | $233.9M |
| Q4 25 | $1.3B | $488.0M | ||
| Q3 25 | $1.3B | $453.3M | ||
| Q2 25 | $1.3B | $435.6M | ||
| Q1 25 | $872.1M | $424.6M | ||
| Q4 24 | $885.0M | $432.7M | ||
| Q3 24 | $877.9M | $390.4M | ||
| Q2 24 | $878.6M | $376.8M | ||
| Q1 24 | $942.6M | $356.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $25.4M | $15.0M |
| Free Cash FlowOCF − Capex | $13.0M | $12.8M |
| FCF MarginFCF / Revenue | 11.5% | 13.8% |
| Capex IntensityCapex / Revenue | 10.9% | 2.4% |
| Cash ConversionOCF / Net Profit | 2.77× | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | $35.1M | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $25.4M | $15.0M | ||
| Q3 25 | $31.4M | $22.1M | ||
| Q2 25 | $15.3M | $8.2M | ||
| Q1 25 | $15.0M | $6.6M | ||
| Q4 24 | $13.5M | $22.2M | ||
| Q3 24 | $8.2M | $10.2M | ||
| Q2 24 | $-181.0K | $18.5M | ||
| Q1 24 | $1.7M | $7.2M |
| Q4 25 | $13.0M | $12.8M | ||
| Q3 25 | $26.3M | $19.5M | ||
| Q2 25 | $-2.9M | $81.0K | ||
| Q1 25 | $-1.3M | $-7.6M | ||
| Q4 24 | $-2.4M | $8.5M | ||
| Q3 24 | $-6.7M | $-9.2M | ||
| Q2 24 | $-2.7M | $1.8M | ||
| Q1 24 | $-1.2M | $-6.8M |
| Q4 25 | 11.5% | 13.8% | ||
| Q3 25 | 31.5% | 28.8% | ||
| Q2 25 | -4.2% | 0.1% | ||
| Q1 25 | -2.1% | -14.5% | ||
| Q4 24 | -3.5% | 11.2% | ||
| Q3 24 | -11.6% | -15.9% | ||
| Q2 24 | -6.3% | 3.4% | ||
| Q1 24 | -3.6% | -13.3% |
| Q4 25 | 10.9% | 2.4% | ||
| Q3 25 | 6.1% | 3.9% | ||
| Q2 25 | 26.2% | 12.9% | ||
| Q1 25 | 27.0% | 27.0% | ||
| Q4 24 | 23.3% | 18.3% | ||
| Q3 24 | 25.7% | 33.5% | ||
| Q2 24 | 5.8% | 31.8% | ||
| Q1 24 | 8.8% | 27.3% |
| Q4 25 | 2.77× | 0.65× | ||
| Q3 25 | — | 4.35× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.12× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SITM
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
